National Clinician Scholar Program, Master of Science in Health Policy Research, Department of Emergency Medicine and Penn Center for Opioid Recovery and Engagement, Perelman School of Medicine at the University of Pennsylvania, PA; Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; The Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA (UGK); Division of Medical Toxicology and Addiction Medicine Initiatives, Penn Medicine Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, PA (JP).
J Addict Med. 2020 Jul/Aug;14(4):e6-e7. doi: 10.1097/ADM.0000000000000684.
: The COVID19 crisis has created many additional challenges for patients with opioid use disorder, including those seeking treatment with medications for OUD. Some of these challenges include closure of substance use treatment clinics, focus of emergency departments on COVID-19 patients, social distancing and shelter in place orders affecting mental health, bystander overdose rescue, threats to income and supply of substances for people who use drugs. While the initial changes in regulation allowing buprenorphine prescribing by telehealth are welcomed by providers and patients, many additional innovations are required to ensure that additional vulnerabilities and hurdles created by this pandemic scenario do not further fan the flames of the opioid epidemic.
: COVID19 危机给阿片类药物使用障碍患者带来了许多额外的挑战,包括那些寻求使用药物治疗 OUD 的患者。这些挑战包括:阿片类物质使用障碍治疗诊所关闭,急诊室专注于 COVID-19 患者,社会隔离和居家令影响心理健康,旁观者过量救援,以及使用毒品的人的收入和供应物质受到威胁。虽然最初允许通过远程医疗开处丁丙诺啡的监管变化受到了提供者和患者的欢迎,但还需要许多额外的创新,以确保这种大流行情况下造成的更多脆弱性和障碍不会进一步助长阿片类药物泛滥。